Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Cost-Effectiveness of Indefinite Versus Short-Term Anticoagulation for the Prevention of Recurrent Venous Thromboembolism in Unprovoked Venous Thromboembolism Patients

FY 2015-16

Summary
Venous thromboembolism (VTE) comprising of blood clots in the legs and the lung vessels, is the third most common cause of cardiovascular mortality, and affects more than 50,000 Canadians each year. Unfortunately, more than50% of VTE patients have no identifiable cause (i.e unprovoked), and the risk of recurrent VTE in these patients can reach 10.8% in the year after stopping 3-6 months of oral anticoagulant therapy (OAT). Choosing short-term or indefinite OAT after a firstunprovoked VTE is a common and difficult clinical decision, as the risk of recurrent fatal VTE must be balanced with the risk of fatal major bleeding. Currently, the financial costs associated with VTE management are extensive, and as the population ages, the economic burden from this disease is anticipated to rise faster than the general increase in medical costs. The objective of this study is to determine the clinical cost-effectiveness of indefinite OAT compared with short-term OAT for the prevention of recurrent VTE, in unprovoked VTE patients. The study will utilize a cost-utility analysis with the target population being Canadian unprovoked VTE patients. The analysis will be conducted from both a healthcare system and a societal perspective. The appraisal of cost-effectiveness is a vital factor in establishing whether a therapy is approved for reimbursement and formulary inclusion. Economic assessment of the duration of anticoagulation is imperative as resources are scarce, and it is critical to attempt to obtain the greatest reduction of VTE recurrence in the most efficient manner. This study will provide potentially definitive evidence to help in the decision-making process of offering clinicians with guidance for the duration of OAT for unprovoked VTE patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
350194
Name
Khan Faizan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cost-Effectiveness of Indefinite Versus Short-Term Anticoagulation for the Prevention of Recurrent Venous Thromboembolism in Unprovoked Venous Thromboembolism Patients
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anticoagulant Therapy; Cost-Effectiveness; Deep Vein Thrombosis; Markov Model; Pulmonary Embolism; Venous Thromboembolism
Abstract
Venous thromboembolism (VTE) comprising of blood clots in the legs and the lung vessels, is the third most common cause of cardiovascular mortality, and affects more than 50,000 Canadians each year. Unfortunately, more than50% of VTE patients have no identifiable cause (i.e unprovoked), and the risk of recurrent VTE in these patients can reach 10.8% in the year after stopping 3-6 months of oral anticoagulant therapy (OAT). Choosing short-term or indefinite OAT after a firstunprovoked VTE is a common and difficult clinical decision, as the risk of recurrent fatal VTE must be balanced with the risk of fatal major bleeding. Currently, the financial costs associated with VTE management are extensive, and as the population ages, the economic burden from this disease is anticipated to rise faster than the general increase in medical costs. The objective of this study is to determine the clinical cost-effectiveness of indefinite OAT compared with short-term OAT for the prevention of recurrent VTE, in unprovoked VTE patients. The study will utilize a cost-utility analysis with the target population being Canadian unprovoked VTE patients. The analysis will be conducted from both a healthcare system and a societal perspective. The appraisal of cost-effectiveness is a vital factor in establishing whether a therapy is approved for reimbursement and formulary inclusion. Economic assessment of the duration of anticoagulation is imperative as resources are scarce, and it is critical to attempt to obtain the greatest reduction of VTE recurrence in the most efficient manner. This study will provide potentially definitive evidence to help in the decision-making process of offering clinicians with guidance for the duration of OAT for unprovoked VTE patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Khan, Faizan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~